Evidence network for deaths_(OS)

1KEYNOTE-021, 20161KEYNOTE-189, 20181IMpower-150 (ABCP vs BPC WT), 20181IMpower-132 (WT), 01IMpower-130 (WT), 2019pemetrexed plus platinplacebo plus SoCbevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelpembrolizumab and pemetrexed plus platinpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinatezolizumab plus carboplatin plus nab-paclitaxeldirect evidencenetwork meta-analysis
T vs. C pemetrexed plus platinplacebo plus SoCbevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelpembrolizumab and pemetrexed plus platinpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinatezolizumab plus carboplatin plus nab-paclitaxel
pemetrexed plus platin---NANANANANANANANA
placebo plus SoCNA---NANANANANANANA
bevacizumab plus carboplatin and paclitaxelNANA---NANANANANANA
carboplatin plus nab-paclitaxelNANANA---NANANANANA
pembrolizumab and pemetrexed plus platinNANANANA---NANANANA
pembrolizumab plus SoCNANANANANA---NANANA
atezolizumab plus bevacizumab plus carboplatin plus paclitaxelNANANANANANA---NANA
atezolizumab plus pemetrexed and platinNANANANANANANA---NA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANA---

pathologies: 176 - treatments: 865 result logic